Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLEXERIL vs BUNAVAIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that prevents misuse via injection.
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
FDA-approved for the treatment of opioid dependence, including induction and maintenance therapy.
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
For moderate to severe opioid use disorder: sublingual film, induction: 2-4 mg buprenorphine/0.5-1 mg naloxone on day 1, then up to 8 mg/2 mg on day 2; maintenance: target 16 mg/4 mg sublingually once daily, range 4-24 mg/1-6 mg daily.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Terminal elimination half-life of buprenorphine is approximately 24-42 hours (mean ~37 hours) due to slow dissociation from mu-opioid receptors, supporting extended dosing intervals.
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Buprenorphine is primarily metabolized via N-dealkylation by CYP3A4 to norbuprenorphine; also undergoes glucuronidation. Naloxone undergoes hepatic metabolism primarily by glucuronidation.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Fecal (~70%) as unconjugated buprenorphine and metabolites; renal (~30%) primarily as conjugated metabolites.
~93% bound to plasma proteins, primarily albumin.
Approximately 96% bound to alpha- and beta-globulins, not significantly to albumin.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
Vd: 2.5-4.0 L/kg, indicating extensive tissue distribution and high lipophilicity.
Oral: ~33% due to extensive first-pass metabolism.
Buccal: ~30-40% relative to intravenous; sublingual: ~30% due to first-pass metabolism; buccal route avoids some gastrointestinal degradation.
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl < 30 m L/min): use with caution; consider dose reduction or extended intervals due to potential accumulation of buprenorphine.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B): reduce starting dose by 50% and titrate slowly. For mild impairment (Child-Pugh class A): no dose adjustment required.
Not recommended for use in children under 15 years old; safety and efficacy not established.
Not approved for patients under 16 years; safety and efficacy not established. For adolescents 16 years and older: use adult dosing based on weight and severity.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
No specific dose adjustment in elderly; use caution due to increased sensitivity, impaired hepatic/renal function, and risk of falls. Start at low end of dosing range and titrate slowly.
None
Risk of addiction, abuse, and misuse; respiratory depression and death with IV administration; neonatal opioid withdrawal syndrome with prolonged use; risk of opioid withdrawal with abrupt discontinuation; risk of hepatitis, hepatic events; precipitation of withdrawal if given to patients dependent on full agonists.
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Respiratory depression; neonatal opioid withdrawal syndrome; hepatic injury; precipitation of opioid withdrawal; risks from concomitant use with benzodiazepines or CNS depressants; dependence and withdrawal; use in patients with compromised respiratory function; increased intracranial pressure; hypotension; biliary tract disease; QT prolongation; impairment of driving/operating machinery.
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
Hypersensitivity to buprenorphine or naloxone; patients with significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; patients not already dependent on opioids (for induction).
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
No significant food interactions. However, patients should avoid grapefruit juice as it may increase buprenorphine levels. Advise to take on an empty stomach for consistent absorption, though food does not significantly alter bioavailability.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
Buprenorphine, a component of BUNAVAIL, is not associated with major congenital malformations. However, third-trimester use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Use in pregnancy only if benefit outweighs risk.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
Buprenorphine is excreted into breast milk in low concentrations; estimated relative infant dose is 2.4% of maternal weight-adjusted dose. M/P ratio is not well established. Caution is advised, monitor for infant sedation and respiratory depression.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
Pregnancy may alter buprenorphine pharmacokinetics; dose adjustments may be needed to avoid withdrawal or oversedation. Monitor clinical response and adjust doses in increments of 2-4 mg sublingual buprenorphine as needed, guided by withdrawal symptoms and cravings.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
BUNAVAIL (buprenorphine/naloxone) sublingual film is indicated for maintenance treatment of opioid dependence. Administer as a single daily dose; films can be cut to achieve lower doses. Avoid abrupt discontinuation to prevent withdrawal. Monitor for respiratory depression, especially during induction. Use with caution in patients with hepatic impairment; naloxone component may precipitate withdrawal in opioid-tolerant patients if injected.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
Place the film under the tongue and allow it to dissolve completely; do not chew, swallow, or move the film after placement.,Do not drink or eat until the film has completely dissolved.,Avoid use of alcohol or other central nervous system depressants (e.g., benzodiazepines) while taking this medication as it may increase risk of respiratory depression.,Do not stop taking this medication suddenly without consulting your healthcare provider as withdrawal symptoms may occur.,Store at room temperature away from moisture and heat; keep out of reach of children.,This medication can cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Inform all healthcare providers that you are taking this medication before any surgery or emergency treatment.,Do not take other opioids, including illicit drugs, while on this medication as it may cause severe withdrawal or overdose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLEXERIL vs BUNAVAIL, answered by our medical review team.
FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. BUNAVAIL is a Opioid Partial Agonist Combination that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that prevents misuse via injection.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLEXERIL and BUNAVAIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. The standard adult dose of BUNAVAIL is: For moderate to severe opioid use disorder: sublingual film, induction: 2-4 mg buprenorphine/0.5-1 mg naloxone on day 1, then up to 8 mg/2 mg on day 2; maintenance: target 16 mg/4 mg sublingually once daily, range 4-24 mg/1-6 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLEXERIL and BUNAVAIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . BUNAVAIL is classified as Category C. Buprenorphine, a component of BUNAVAIL, is not associated with major congenital malformations. However, third-trimester use may cause neonatal opioid withdrawal syndrome (NOWS) and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.